Amplify Weight Loss Drug & Treatment ETF (THNR) Stock Price, Quote, News & History

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Sector

Healthcare

Region

AUM

5.35M

Fund Score

Key Statistics

Open

$25.51

High

$25.59

52 Wk High

$27.94

AUM

5.35M

Dividend

$0.41

Ex-Div Date

Dec 30, 2025

Volume

1.16K

Market Cap

$204.83B

Mgmt Fee

0.59%

P/E Ratio

28.80

Prev. Close

$25.70

Low

$25.51

52 Wk Low

$22.63

Shares Out

200.00K

Yield

1.61%

Div. Freq

Avg. Volume Daily

1.88K

Beta

0.39

Avg. Expense Ratio

0.59%

P/B Ratio

5.59

Recent Amplify Weight Loss Drug & Treatment ETF News

Food Companies Rethink Menus For GLP-1 Users As Wegovy Weight Loss Pill Gets Approval

Food makers and restaurants adjust menus and products as GLP-1 drugs drive demand for high-protein foods and smaller portions across the U.S.

Vandana Singh

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs

The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.

Chandrima Sanyal

Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares

Recently, the company announced a massive $15 billion share buyback plan and a 15% dividend increase.

Pooja Rajkumari

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'

Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.

Piero Cingari

ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential

New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments.

Vandana Singh

FAQ

How do I buy Amplify Weight Loss Drug & Treatment ETF (THNR) stock?

You can purchase shares of Amplify Weight Loss Drug & Treatment ETF (ARCA:THNR) through any online brokerage.

View our list of the best stock brokerages

Who are Amplify Weight Loss Drug & Treatment ETF (THNR) competitors?

There are no as such competitors for Amplify Weight Loss Drug & Treatment ETF.

What is the forecast, or price target, for Amplify Weight Loss Drug & Treatment ETF (THNR) stock?

There is no analysis for Amplify Weight Loss Drug & Treatment ETF to provide a consensus price target.

What is the current price for Amplify Weight Loss Drug & Treatment ETF (THNR)?

The stock price for Amplify Weight Loss Drug & Treatment ETF (ARCA: THNR) is $25.59 last updated September 11, 2026 at 8:00 PM EDT.

Does Amplify Weight Loss Drug & Treatment ETF (THNR) pay a dividend?

There are no upcoming dividends for Amplify Weight Loss Drug & Treatment ETF.

When is Amplify Weight Loss Drug & Treatment ETF (ARCA:THNR) reporting earnings?

Amplify Weight Loss Drug & Treatment ETF does not have any upcoming earnings scheduled.

Is Amplify Weight Loss Drug & Treatment ETF (THNR) going to split?

There is no upcoming split for Amplify Weight Loss Drug & Treatment ETF.

Key Statistics

Open

$25.51

High

$25.59

52 Wk High

$27.94

AUM

5.35M

Dividend

$0.41

Ex-Div Date

Dec 30, 2025

Volume

1.16K

Market Cap

$204.83B

Mgmt Fee

0.59%

P/E Ratio

28.80

Prev. Close

$25.70

Low

$25.51

52 Wk Low

$22.63

Shares Out

200.00K

Yield

1.61%

Div. Freq

Avg. Volume Daily

1.88K

Beta

0.39

Avg. Expense Ratio

0.59%

P/B Ratio

5.59

About

Sector

N/A

Industry

N/A

ETF Details

Sector	Healthcare
Category	Mid Performer-Mid Growth
Investment Style	Large Cap Blend
Fund Inception	May 21, 2024
Managers	Dustin Lewellyn Ernesto Tong
Definition	Most of the stocks in this equity fund have average financial performance and average growth potential

Investment Policy

The Index is comprised of global companies expected to economically benefit from weight loss drug development. The Index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs.

Top ETF Holdings

Symbol	Name	Share %
LLY	Eli Lilly & Co.	8.90%
CO	Novo Nordisk A/S ADR	9.35%
REGN	Regeneron Pharmaceutic...	5.96%
HK	CSPC Pharmaceutical Gr...	5.44%
ARWR	Arrowhead Pharmaceutic...	5.31%
SM	Roche Holding Ltd. Ord...	5.20%
ABBV	Abbvie Inc.	4.94%
SRRK	Scholar Rock Holding C...	5.34%
KY	Innovent Biologics Inc	5.83%
AMGN	Amgen Inc.	5.39%